Acquired Amegakaryocytic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia: A Case Report.

Introduction: Acquired amegakaryocytic thrombocytopenia (AATP) is a rare bleeding disorder that causes severe thrombocytopenia with preserved hematopoiesis of other cell lineages. Many cases are misdiagnosed and treated as immune thrombocytopenia.

Case Presentation: We report a case of AATP, in a 50-year-old man, that was treated as immune thrombocytopenia for years with no clinical response.

Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma.

Patients with renal cell carcinoma (RCC) often remain asymptomatic until the disease is advanced, with about 25% presenting at an advanced stage. We present a case of metastatic RCC treated with combination ipilimumab and nivolumab with complete radiological and pathological response. Currently, combination nivolumab and ipilimumab is a preferred option for intermediate- and poor-risk patients with clear cell stage IV RCC.

A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy.

Introduction: Prognosis of metastatic castrate-resistant prostate cancer is poor with a median survival of 12 to 36 months. Bone metastasis is common, and bone marrow metastasis occurs later in the disease course. The median survival in these patients after bone marrow involvement is less than six months.

Updates on Cancer Survivorship Care Planning.

Cancer organizations have developed guides and tools to help build cancer survivorship programs and survivorship care plans.

Multiple Myeloma: Updates on Diagnosis and Management.

Two- and 3-drug treatment regimens and autologous stem cell transplants provide opportunities for longer term disease remission, though most patients will still develop relapsed multiple myeloma.

Castleman Disease.

An understanding of the disease pathogenesis has led to the discovery of therapuetic agents that target human herpesvirus-8 replication, CD20, and IL-6 and IL-6R antibodies.

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

Objectives: Although the reported incidence of carboplatin hypersensitivity is low, its occurrence is important to characterize because of potential fatal complications. The purpose of this study was to determine the current incidence of carboplatin hypersensitivity in the ovarian cancer patients compared to other oncology patients and identify potential risk factors that may contribute to development of carboplatin hypersensitivity reactions.

Methods: This was a retrospective chart review analyzing all hospital records at an academic tertiary oncology center between July 2002 and September 2003.

Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature.

We reviewed the incidence of diagnosis of renal cell carcinoma and lymphoma in the same patient and analyzed the characteristics of this association. Nine patients in 4 years had the diagnosis of renal cell carcinoma (RCC) and lymphoma, including 2 with Hodgkin disease, 1 with chronic lymphocytic leukemia (CLL), and 3 each with low-grade follicular and intermediate-grade non-Hodgkin lymphoma (NHL). In SEER data, the observed/expected (O/E) ratio of NHL and RCC is 1.